Relay Therapeutics, Inc. (RLAY) Tops Q3 EPS by 14c

Relay Therapeutics, Inc. (NASDAQ: RLAY) reported Q3 EPS of ($0.63), $0.14 better than the analyst estimate of ($0.77). Revenue for the quarter came in at $0 versus the consensus estimate of $88.89 thousand.

For earnings history and earnings-related data on Relay Therapeutics, Inc. (RLAY) click here.

You May Also Be Interested In

• EyePoint Pharmaceuticals (EYPT) call put ratio 1.4 calls to 1 put as share price up 8.9%
• Sypris Solutions (SYPR) Reports Q2 Loss of $0.14
• Eltek Ltd (ELTK) Reports Q2 EPS of $0.41